Two to three cycles per year maintain telomere length without the theoretical risks of sustained telomerase upregulation
Dehghani F, Sezavar Seyedi Jandaghi SH, Janani L, Sarebanhassanabadi M, Emamat H, Vafa M
Future pharmaceutical CagriSema Anticipated FDA approval: Phase 3 trials completed FDA submission expected 2024-2025 Approval likely 2025-2026 Brand name: CagriSema Pharmaceutical pricing (projected): Likely $1,200-1,500/month without insurance Similar to Wegovy/Zepbound pricing Insurance coverage uncertain initially Patient assistance programs may be available Insurance considerations: May cover if BMI 30 with comorbidity Or BMI 27 with diabetes/hypertension Prior authorization required Step therapy (try semaglutide first) When pharmaceutical available: Easier administration (pre-filled pen likely) Medical support included Quality guaranteed Prescription required May or may not be cheaper than research peptides Troubleshooting CagriSema dosing issues Common problems and solutions
Repeated exposure to harsh cleansers, excessive exfoliation, and UV damage increases transepidermal water loss (TEWL), slowing skin barrier healing
The real ones we watch for: injection-site reactions, effects on your own hormone production, and changes in glucose control with growth hormone secretagogues
What are the side effects of copper peptides
